Fig. 1From: The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humansMaximum intensity projections (MIP) obtained at different time points after administration for one representative subject 135. MIP images for additional subjects 105 and 127 are provided in the Additional file 1: Figures S2 and S4Back to article page